A Randomized, Double Blinded, Vehicle-Controlled Study to Evaluate the Safety and the Effect on Sweat Production of Topically Applied BBI-4000 in Subjects With Hyperhidrosis.

Trial Profile

A Randomized, Double Blinded, Vehicle-Controlled Study to Evaluate the Safety and the Effect on Sweat Production of Topically Applied BBI-4000 in Subjects With Hyperhidrosis.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2014

At a glance

  • Drugs Sofpironium bromide (Primary)
  • Indications Hyperhidrosis
  • Focus Therapeutic Use
  • Sponsors Brickell Biotech
  • Most Recent Events

    • 24 Sep 2014 Preliminary results published in a Brickell Biotech media release.
    • 24 Sep 2014 Primary endpoint (change in sweat production from baseline at week 2) has been met, according to a Brickell Biotech media release.
    • 10 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top